OncoKB Therapeutic Levels of Evidence

FDA-recognized biomarker predictive of response to an FDA-approved drug in this indication

2A **Standard care** biomarker predictive of response to an FDA-approved drug in this indication*

2B Standard care biomarker predictive of response to an FDA-approved drug in another indication, but not standard care in this indication

Compelling clinical evidence supports the biomarker as being predictive of response to a drug in this indication

Compelling clinical evidence supports the biomarker as being predictive of response to a drug in another indication

Compelling biological evidence supports the biomarker as being predictive of response to a drug

Standard care biomarker predictive of **resistance** to an FDA-approved drug in this indication

Compelling clinical evidence supports the biomarker as being predictive of resistance to a drug

Standard **Therapeutic Implications**

*Includes biomarkers that are recommended as standard care by the NCCN or other expert panels but not necessarily FDArecognized for a particular indication

Investigational Therapeutic **Implications**

possibly directed to clinical trials

Hypothetical Therapeutic **Implications** based on preliminary, non-clinical data

Standard Resistance **Implications**

Investigational Resistance **Implications**

based on clinical data

R1

3A

3B

4

R2